175 related articles for article (PubMed ID: 28887119)
1. Respiratory syncytial virus associated hospitalizations in children with congenital diaphragmatic hernia.
Resch B; Liziczai K; Reiterer F; Freidl T; Haim M; Urlesberger B
Pediatr Neonatol; 2018 Apr; 59(2):184-188. PubMed ID: 28887119
[TBL] [Abstract][Full Text] [Related]
2. Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017.
Kim D; Saleem M; Paes B; Mitchell I; Lanctôt KL
Clin Infect Dis; 2019 Aug; 69(6):980-986. PubMed ID: 30517603
[TBL] [Abstract][Full Text] [Related]
3. Respiratory syncytial virus bronchiolitis in congenital diaphragmatic hernia: A systematic review of prevalence rates and palivizumab prophylaxis.
Lewis L; Sinha I; Losty PD
Pediatr Pulmonol; 2022 Jan; 57(1):239-244. PubMed ID: 34617409
[TBL] [Abstract][Full Text] [Related]
4. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
Resch B; Egger B; Kurath-Koller S; Urlesberger B
Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
[TBL] [Abstract][Full Text] [Related]
5. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
6. Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study.
Elhalik M; El-Atawi K; Dash SK; Faquih A; Satyan AD; Gourshettiwar N; Khan A; Varughese S; Ramesh A; Khamis E
Can Respir J; 2019; 2019():2986286. PubMed ID: 31871513
[TBL] [Abstract][Full Text] [Related]
7. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
[TBL] [Abstract][Full Text] [Related]
8. Respiratory Syncytial Virus Infection-associated Hospitalization Rates in Infants and Children With Cystic Fibrosis.
Metz J; Eber E; Resch B
Pediatr Infect Dis J; 2017 Jun; 36(6):545-548. PubMed ID: 28005688
[TBL] [Abstract][Full Text] [Related]
9. Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience.
Rajah B; Sánchez PJ; Garcia-Maurino C; Leber A; Ramilo O; Mejias A
J Pediatr; 2017 Feb; 181():183-188.e1. PubMed ID: 27855996
[TBL] [Abstract][Full Text] [Related]
10. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for respiratory syncytial virus bronchiolitis hospitalizations in children with chronic diseases.
Shmueli E; Goldberg O; Mei-Zahav M; Stafler P; Bar-On O; Levine H; Steuer G; Mussaffi H; Gendler Y; Blau H; Prais D
Pediatr Pulmonol; 2021 Jul; 56(7):2204-2211. PubMed ID: 33913611
[TBL] [Abstract][Full Text] [Related]
12. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
Resch B
Hum Vaccin Immunother; 2017 Sep; 13(9):2138-2149. PubMed ID: 28605249
[TBL] [Abstract][Full Text] [Related]
13. Risk of respiratory syncytial virus in survivors with severe congenital diaphragmatic hernia.
Masumoto K; Nagata K; Uesugi T; Yamada T; Kinjo T; Hikino S; Hara T; Taguchi T
Pediatr Int; 2008 Aug; 50(4):459-63. PubMed ID: 19143967
[TBL] [Abstract][Full Text] [Related]
14. Palivizumab use in infants with Down syndrome-report from the German Synagis™ Registry 2009-2016.
Simon A; Gehrmann S; Wagenpfeil G; Wagenpfeil S
Eur J Pediatr; 2018 Jun; 177(6):903-911. PubMed ID: 29651734
[TBL] [Abstract][Full Text] [Related]
15. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.
Kua KP; Lee SWH
Pharmacotherapy; 2017 Jun; 37(6):755-769. PubMed ID: 28423192
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
Hashmi NA; Cosgrove JF; MacMahon P
Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
[TBL] [Abstract][Full Text] [Related]
17. Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study : Palivizumab prophylaxis in children with congenital heart disease.
Ratti C; Greca AD; Bertoncelli D; Rubini M; Tchana B
Ital J Pediatr; 2023 Jan; 49(1):4. PubMed ID: 36631870
[TBL] [Abstract][Full Text] [Related]
18. Cost Savings Without Increased Risk of Respiratory Hospitalization for Preterm Children after the 2014 Palivizumab Policy Update.
Levin JC; Beam AL; Fox KP; Hayden LP
Am J Perinatol; 2024 May; 41(S 01):e133-e141. PubMed ID: 35523410
[TBL] [Abstract][Full Text] [Related]
19. Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis.
Resch B; Bramreiter VS; Kurath-Koller S; Freidl T; Urlesberger B
Eur J Clin Microbiol Infect Dis; 2017 Jun; 36(6):1057-1062. PubMed ID: 28078558
[TBL] [Abstract][Full Text] [Related]
20. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
Paes B; Steele S; Janes M; Pinelli J
Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]